Jeff Scheele
Founder and CEO
Replay available
Aktis Oncology, Inc. (NASDAQ: AKTS) Q4 2023 earnings conference call, held 2023-09-06. Replay captured from the company's public earnings webcast.

Founder and CEO
Chief Financial Officer
Analyst
EVP of Business Development
Analyst at B. Reilly Securities
Analyst at Rotham Cam
Good day, ladies and gentlemen, and welcome to the Acoustis Technologies Fiscal 2023 Fourth Quarter Conference Call. As a reminder, this conference call is being recorded. At the conclusion of the company's presentation, Acoustis Management will take questions. To ask a question, please press star 1 on your telephone keypad to be placed in the queue. A replay of the call will be available on the Investor Relations section of the Acoustis website. I would now like to turn the floor over to Tom Sapenzis. Thank you, Operator, and good morning to everyone on the call. Welcome to ACOUSTA's fourth quarter fiscal 2023 conference call. We are joined today by our founder and CEO, Jeff Scheele, CFO Ken Bowler, and EVP of Business Development, Dave Eichle. Before we begin, please note that today's presentation includes forward-looking statements about our business outlook. All statements other than statements of historical facts included in this conference call such as expectations regarding our strategies and operations, including the timing and prospects of product development and customer orders and design wins, possible collaborative or partnering relationships, litigation matters, and expected financial and operating results, are forward-looking statements. Such forward-looking statements are predictions based on the company's expectations as of today and are subject to numerous risks and uncertainties. The company... and our management team assume no obligation to update any forward-looking statements made on today's call. Our SEC filings mention important factors that could cause actual results to differ materially. Please refer to our latest Form 10-K and Form 10-Q filed with the SEC to get a better understanding of those risks and uncertainties. In addition, our presen...